A continuously operated single stage mixedsuspension, mixed-product-removal (MSMPR) crystallizer using intermittent withdrawal via a dip pipe with combined pressure/vacuum was successfully developed for the manufacture of active pharmaceutical ingredients. Approximately 5.8% of the total operating volume was intermittently removed at a high velocity using vacuum. The transfer line was also periodically purged with nitrogen to ensure complete removal of residual solids. In situ process analytical technologies (focused beam reflective measurement (FBRM) and process video microscopy (PVM)) were successfully applied to monitor and characterize the MSMPR crystallization process. In this study, a cooling crystallization of paracetamol from an aqueous isopropyl alcohol solution was investigated. Experimental results indicate that the crystallization system was able to operate without any clogging issues for over 10 residence times, before which the system had approached steady state. Three different start-up strategies for continuous crystallization were investigated, and the results indicate that the chord length distributions at steady state were the same for all cases. Also, starting the continuous operation from a saturated solution that was seeded with product from a previous MSMPR run offered the quickest route to steady state. To better control and scale up the crystallization process, the nucleation and crystal growth kinetics of the model compound were also determined through use of the newly developed process. The growth rates were found to be size dependent, and an exponential three-parameter model was employed to characterize the size-dependent growth. It was seen that the crystal growth rate was extremely low and increased linearly with particle size when the particle size was below 10 μm. However, the growth rate increased dramatically with particle size when the particle size was between 10 and 1000 μm. The nucleation kinetics was correlated by the semiempirical equation B TOT = 1.11 × 10 15 M T 0.98 G avg 1.12 . The orders of the total nucleation rate with respect to the magma density and average growth rate were 0.98 and 1.12, respectively. Therefore, the effect of supersaturation (or residence time) and magma density on the steady state crystal size was investigated.
Hyperbranched
polysiloxane (HBPSi) is attracting increasing attention
due to its intrinsic fluorescence and good biocompatibility. However,
it is very challenging to explore its biological applications because
of the low fluorescence intensity and quantum yield. Herein, we introduced
rigid β-cyclodextrin to the end of flexible polysiloxane chain
to synthesize a novel fluorescent polymer (HBPSi-CD) and explore its
biological applications. Results showed that the fluorescence intensity
and quantum yield of HBPSi-CD, compared with HBPSi, were significantly
enhanced. Theoretical calculations and transmission electron microscopy
demonstrated that the synergy effect of intra/intermolecular hydrogen
bonds and hydrophobic effect promoted the formation of large supramolecular
self-assemblies and space electron delocalization systems, leading
to intense fluorescence. Notably, the biocompatible HBPSi-CD not only
lighted up mouse fibroblast cells, but also possessed high ibuprofen
loading capacity (160 mg g–1) and superior pH-responsive
drug release performance. This work promoted the development of biological
applications of HBPSi.
The presented work shows an impressive multicolour luminescence hyperbranched polysiloxane attributed to the multiring through-space conjugation named “multiring induced multicolor emission” (MIE), as well as its application in data encryption.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.